225Ac-PSMA-617 for therapy of prostate cancer
C Kratochwil, U Haberkorn, FL Giesel - Seminars in nuclear medicine, 2020 - Elsevier
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-
emitting 177 Lutetium has already been investigated in several early phase dosimetry …
emitting 177 Lutetium has already been investigated in several early phase dosimetry …
[HTML][HTML] Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
RM Pallares, RJ Abergel - Frontiers in medicine, 2022 - frontiersin.org
Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation
are locally delivered to tumor cells, while the surrounding healthy tissue is minimally …
are locally delivered to tumor cells, while the surrounding healthy tissue is minimally …
Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA
B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti… - European urology, 2021 - Elsevier
Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients
MJ Zacherl, FJ Gildehaus, L Mittlmeier… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Treatment of advanced metastatic castration-resistant prostate cancer after failure of
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA) …
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA) …
[HTML][HTML] Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer
A Juzeniene, VY Stenberg, ØS Bruland, RH Larsen - Cancers, 2021 - mdpi.com
Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …
[HTML][HTML] Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM …
T Langbein, HR Kulkarni, C Schuchardt, D Mueller… - Diagnostics, 2022 - mdpi.com
Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high …
patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high …
[HTML][HTML] Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
VY Stenberg, RH Larsen, LW Ma, Q Peng… - International journal of …, 2021 - mdpi.com
Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) is rapidly
evolving as a promising treatment for metastatic castration-resistant prostate cancer. The …
evolving as a promising treatment for metastatic castration-resistant prostate cancer. The …
[HTML][HTML] Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
D Arbuznikova, M Eder, AL Grosu, PT Meyer… - Current Oncology …, 2023 - Springer
Abstract Purpose of Review [177Lu] Lu-PSMA-617 is a radiopharmaceutical that emits beta-
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …
[HTML][HTML] Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer–a narrative review
P Szponar, P Petrasz, K Brzeźniakiewicz-Janus… - Frontiers in …, 2023 - frontiersin.org
Introduction Radio-ligand targeted therapy is a new and promising concept of treatment
Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were …
Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were …
[HTML][HTML] Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-
overexpressing diseases, especially prostate cancer-a common type of cancer among men …
overexpressing diseases, especially prostate cancer-a common type of cancer among men …